UroGen Pharma Ltd. (URGN) Guidance & Earnings Results
On 2026-08-05 UroGen Pharma Ltd. reaffirmed guidance: "JELMYTO full-year 2026 guidance range of $97M to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
URGNUroGen Pharma Ltd.Follow URGN — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Reaffirmed | JELMYTO full-year 2026 guidance range of $97M to $101M · full year |
| 7 Aug 25 | Reaffirmed | FY2025 JELMYTO net product revenue $94-98M; FY2025 operating expenses $215-225M including non-cash share-based compensation $11-14M · full year |
UroGen Pharma Ltd. — questions
- What guidance did UroGen Pharma Ltd. give?
- On 2026-08-05: "JELMYTO full-year 2026 guidance range of $97M to $101M"
- When does UroGen Pharma Ltd. report earnings?
- UroGen Pharma Ltd.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from UroGen Pharma Ltd.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.